Last updated 5 days ago

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

100 patients around the world

Available in Argentina, United States

Eli Lilly and Company

6Research sites

100Patients around the world

This study is for people with

Diabetes

Diabetes mellitus type 2

To 70 Years

All Gender

: Have type 2 diabetes.
Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening.
Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive.
Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2).

CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Av. Pueyrredón 1746 2° A, C1119 Cdad. Autónoma de Buenos Aires, Argentina

Centro Médico Maffei - CABA, Buenos Aires

Av. Cerviño 3375, CABA, Buenos Aires

Instituto Centenario

Av. Rivadavia 3855, CABA, Buenos Aires

Mautalen - Salud e Investigación - CABA

Azcuénaga 1860 piso 8, C1128AAF Cdad. Autónoma de Buenos Aires, Argentina

Consultorio de Investigación Clínica EMO SRL

Eduardo Acevedo 42 1d, C1405BUB Cdad. Autónoma de Buenos Aires, Argentina

Instituto Medico Catamarca "IMEC"

Catamarca 2031, Rosario, Santa Fe

SponsorEli Lilly and Company

Study typeInterventional

Conditions

Diabetes mellitus type 2

Requirements

To 70 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07215312